Pharma, Pain and Punditry: Mark your calendar for AIPPI's end of year events

The IPKat was walking behind the AIPPI logo the
other day and was struck by how much it
resembles the face and whiskers of a Kat...
For readers who love pharma and their instructing lawyers so much,
then you must register for AIPPI UK's "Pharma IP- the in-house perspective":
Date:  Tuesday, 22 November 2016 
Time:  5:30 PM for a 6PM start.  
Where:  Bird & Bird's swanky new offices (although she hears some people have to sit in open plan....shudder)  (12 New Fetter Lane, London, EC4A 1JP) 
Who:  Nick Finnie (Head of Legal Operations and IP Management at Novartis) and Ravinder Chahil (Director of IP at Polpharma Group.  
What:  Nick and Ravinder will be providing their personal and practical insights on the world of pharma as they discuss the scope of the in-house role, legal hot-topics, wrestling with national IP rights in a global organization and what keeps them awake at night.  They will also be providing their views on the differences between private practice and in-house, what makes for a successful relationship with external counsel and what drives them crazy about external counsel (the AmeriKat added that last bit, but she hopes they speak to that as well).  
How much:  Free for UK AIPPI Members (and if you are not a AIPPI Member, get involved).  £25 for non-UK AIPPI Members.  
To Register:  Click here.   
For readers who just cannot get enough of the pregabalin litigation in the wake of the Court of Appeal's decision upholding Mr Justice Arnold's decision that Warner-Lambert's second medical use patent was invalid then AIPPI's UK Group has an event for you!  
Date:  Tuesday, 29 November 2016 
Time:  5:30 PM for a 6PM start.  Drinks after.  
Where:  Freshfields Bruckhaus Deringer (65 Fleet Street, London E4Y 1JS) 
Who:  A patent attorney, a barrister and a solicitor.  No, its not the start of a joke, but the identities of the three speakers who take the form of Claire Baldock (Boult Wade Tennant), Stuart Baran (Three New Square) and Brian Cordery (Bristows) 
What:  Bringing their unique perspectives, the speakers will be analyzing the Court of Appeal's decision, dealing with the three main aspects of validity, abuse of process and infringement.  For those who attended AIPPI's last Rapid Response seminar following Mr Justice Arnold's decision, you will notice that the speaker line up is the same.  The event will give you an opportunity to cross-examine the speakers on their previous views.  
How much:  Free for UK AIPPI Members (and if you are not a AIPPI Member, again, get involved).  £25 for non-UK AIPPI Members.  
To Register:  Click here.   
For readers who love nothing more than sitting back and listening to a barrister from 8 New Square do the heavy lifting in recapping the year's patent cases, then you better be at Hogan Lovells on 15 December 2016 when "a QC from 8 New Square" will present "On the edge of your seat:  Recent UK Patent Cases".  The event kicks off at 5:30 PM (for 6PM).  Registration is not yet open but will be in a few weeks.

Pharma, Pain and Punditry: Mark your calendar for AIPPI's end of year events Pharma, Pain and Punditry: Mark your calendar for AIPPI's end of year events Reviewed by Annsley Merelle Ward on Tuesday, November 15, 2016 Rating: 5

No comments:

All comments must be moderated by a member of the IPKat team before they appear on the blog. Comments will not be allowed if the contravene the IPKat policy that readers' comments should not be obscene or defamatory; they should not consist of ad hominem attacks on members of the blog team or other comment-posters and they should make a constructive contribution to the discussion of the post on which they purport to comment.

It is also the IPKat policy that comments should not be made completely anonymously, and users should use a consistent name or pseudonym (which should not itself be defamatory or obscene, or that of another real person), either in the "identity" field, or at the beginning of the comment. Current practice is to, however, allow a limited number of comments that contravene this policy, provided that the comment has a high degree of relevance and the comment chain does not become too difficult to follow.

Learn more here:

Powered by Blogger.